Prognostic value and morphological findings of overexpression of glypican-3 in hepatocellular carcinoma. Issue 1 (12th September 2022)

• Record Type: Journal Article
• Authors: Karaoğullarindan, Ümit; Gümürdülü, Yüksel; Üsküdar, Oguz; Odabaş, Emre; Güler, Hasan Selim; Tozluklu, Nur; Bağir, Emine; Kuran, Sedef
• Is Part Of: European journal of gastroenterology & hepatology. Volume 35:Issue 1(2023)
• Page Start: 89
• Page End: 93
• Publication Date: 2022-09-12
• Subjects: hepatocellular carcinoma -- glypican-3 -- prognosis -- survival -- tumor features; Digestive organs -- Diseases -- Periodicals; Liver -- Diseases -- Periodicals; Digestive organs -- Diseases; Liver -- Diseases; Periodicals; 616.33
• DOI: 10.1097/MEG.0000000000002452
• Languages: English
• ISSNs: 0954-691X

Abstract

Abstract : Objectives: Hepatocellular carcinoma (HCC) is the seventh most common cancer all worldwide and is second in cancer-related deaths. In HCC, whose prognosis is still not good despite current treatments, there is a need for prognostic markers as well as early diagnosis. Glypican (GPC)-3 has been proposed as a potential serologic and histochemical marker specific to HCC. This study aimed to determine the relationship between GPC3 overexpression and HCC prognosis and clinicomorphologic features. Materials and methods: In total 152 patients who were diagnosed as a result of hepatectomy, lobectomy or liver transplantation were enrolled. The patients were divided into two groups, GPC3-positive (overexpression) (>10%) and GPC3-negative (<10%). The demographic data of the patients, tumor characteristics and survival times were recorded. Results: Survival was significantly lower in the GPC3+ group. In the multivariate analysis, hepatitis C, AFP, tumor number, tumor focality, portal vein tumor thrombosis and GLP3 positivity were found to be independent risk factors for survival. Conclusion: Our study shows that GPC3 overexpression is a poor prognostic factor in HCC. GPC3 positivity were found to be an independent risk factor for survival.